|
||||
![]() The 16,700-square-foot facility currently houses 22 employees, and the medical firm plans to grow that number to 115 over the next year. More than half of those staffers will be proficient in laboratory sciences and information technology. They will support Aviir's work to provide physicians with the tools and information to reduce the chance of heart disease and lower medical costs, among other goals, according to the company. “There is currently a significant yet unmet clinical need in the medical community for more effective ways to identify individuals at high risk of a heart attack who are missed by current evaluation methods," said Douglas Harrington, M.D., CEO of Aviir. "Providing an accurate assessment of the patient’s overall heart health is the first step in prevention of cardiovascular disease." The new facility is Clinical Laboratory Improvement Amendments (CLIA) certified, and will provide a proprietary test that identifies high-risk patients by measuring rare blood markers of vascular inflammation later this year, as well as other cardiac lab and heart disease gene analyses. The space also will offer risk assessment and therapeutic monitoring of insulin resistance, metabolic syndrome, peripheral arterial disease and stroke. Founded in 2005, Aviir is a privately held company that develops and markets diagnostic and predictive cardiovascular tests. "At Aviir, our ultimate goal is to help physicians identify those patients who are at serious risk of experiencing a heart attack but are completely unaware of their precarious condition," said Harrington. "Armed with better information, physicians will be able to tailor more individualized treatment plans with the goals of improving patient therapeutic compliance, reducing their risk of heart attacks, and decreasing the overall cost of care." Related headlines Affinity Medical Technologies moves to Costa Mesa Irvine-based Cardiogenesis poised for acquisition Irvine-based Susan's Healthy Gourmet introduces 'Good $ense Menu' |
||||
| Comment at 4/5/2011 |